Myovant Sciences GmbH   Report issue

For profit Phase 1 Phase 3
Founded: London United Kingdom (2016)
Status: Acquired by Sumitomo Dainippon (2019)

Organization Overview

First Clinical Trial
2016
NCT04978688
First Marketed Drug
2020
relugolix
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Myovant Sciences | MYOVANT SCIENCES | Myovant Sciences GmbH